Home > Insider Trading > Filing (0001711279-23-000046)

Filing Details

Accession Number:: 0001711279-23-000046
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-06-09 19:03:48
Reporting Period:: 2023-06-08

Accepted Time:: 2023-06-09 19:03:48
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1711279	Krystal Biotech Inc.	KRYS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1198325	Daniel Janney	C/O Krystal Biotech, Inc. 2100 Wharton Street, Suite 701 Pittsburgh PA 15203		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-06-08	4,604	$127.96	152,758	No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
Common Stock	Disposition	2023-06-08	1,073	$129.02	151,685	No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
Common Stock	Disposition	2023-06-08	5,388	$128.73	146,297	No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
Common Stock	Disposition	2023-06-08	5,000	$127.96	141,297	No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
Common Stock	Disposition	2023-06-08	10,000	$127.96	131,297	No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
Common Stock	Disposition	2023-06-08	5,000	$127.86	126,297	No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
Common Stock	Disposition	2023-06-09	3,935	$129.29	122,362	No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
Common Stock	Disposition	2023-06-09	5,000	$128.84	117,362	No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
Common Stock	Disposition	2023-06-09	10,000	$128.53	107,362	No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.
No	4	S	Indirect	Directly beneficially owned by Alta Bioequities, L.P.

Footnotes

Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
The transaction was executed in multiple trades ranging from $129.0000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $128.5000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $127.7000 to $128.44. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $129.0000 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $128.5000 to $129.4800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
The transaction was executed in multiple trades ranging from $127.715 to $129.6100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.